[Pegylated interferon beta-1a on the Italian market]

Mario Eandi

[Editorial in Italian]

pegInterferon beta-1a; Multiple Sclerosis; Italy

MSIF - Multiple Sclerosis International Federation. Atlas of MS 2013. Accessibile all’indirizzo web: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf (ultimo accesso novembre 2015)
AISM - Associazione Italiana Sclerosi Multipla. Bilancio sociale AISM 2014. Accessibile all’indirizzo web: http://bilanciosociale.aism.it (ultimo accesso novembre 2015)
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. The 2013 revisions. Neurology 2014; 83: 278-86; http://dx.doi.org/10.1212/WNL.0000000000000560
Canal N, Ghezzi A, Zaffaroni M. Sclerosi multipla. Attualità e prospettive. Milano: Elsevier Health Sciences, 2011
Howley A, Kremenchutzky M. Pegylated interferons: a nurses’ review of a novel multiple sclerosis therapy. J Neurosci Nurs 2014; 46: 88-96; http://dx.doi.org/10.1097/JNN.0000000000000039
Calabresi PA, Kieseier BC, Arnold DL, et al; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13: 657-65; http://dx.doi.org/10.1016/S1474-4422(14)70068-7
Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2015; 21: 1025-35; http://dx.doi.org/10.1177/1352458514557986

Abstract: 600 views
HTML: 722 views
PDF: 372 views